U.S. Botulinum Toxin Market Size, Share & Industry Analysis, By Application (Therapeutics {Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Blepharospasm, and Others}, and Aesthetics {Forehead Wrinkles, Glabellar Lines, Crow's Feet, and Others}), By Type (Botulinum Toxin Type A and Botulinum Toxin Type B), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others) and Forecast, 2023-2030

The U.S. botulinum toxin market size was valued at USD 4.58 billion in 2022. The market is projected to grow from USD 4.74 billion in 2023 to USD 6.68 billion by 2030, exhibiting a CAGR of 5.0% during the forecast period.

Botulinum toxin injections have wide usage in terms of cosmetology as they block the nerve signals to the muscle in which it was injected and they prevent muscle contraction, which results in a youthful appearance. This trend of cosmetic care has been growing tremendously, and it is expected to continue and strengthen in the coming years.

These products have several aesthetic as well as therapeutic applications. The key factors driving this trend include the increasing prevalence of chronic diseases resulting in the high number of patients requiring these procedures. Similarly, strong product adoption amongst the aging population to reduce wrinkles and fine lines coupled with favorable reimbursement policies for therapeutics drives market growth. In addition, the growing number of cosmetic procedures due to the easy availability of these products and the increasing number of neurotoxin products in the pipeline have also contributed to the overall U.S. botulinum toxin market growth.

COVID-19 Impact

Decline in Number of Patient Visits for Cosmetic Procedures Amid COVID-19 to Impact Negatively on the Market

The COVID-19 pandemic negatively impacted the U.S. market. Due to the pandemic, there was a lockdown and fear of infection amongst the U.S. population, which resulted in the cancellation of cosmetic procedures. Similarly, the fear of virus infection amongst the patients also declined the visits volume to the dermatology clinics. The prominent market player AbbVie recorded a decrease of 17.0% in revenue in 2020 compared to 2019 for their ‘Botox’ segment in the U.S. However, the rising campaign initiatives by key players to seemingly attract customers supported the resurgence of market growth after the pandemic.

• According to an article published by Fierce Pharma in 2020, the key players and dermatology clinics were utilizing social media platforms such as Facebook to tout neurotoxin offerings and encouraging clients to book in advance or come in as soon as they were allowed to open during a lockdown.

In 2021, product adoption and patient visits increased witnessing a strong resurgence. For instance, AbbVie’s product of Botox Cosmetic witnessed an increase of 107.3% in terms of sales in 2021 for the U.S. segment as compared to 2020. The market is expected to witness strong growth trends in the forecast period of 2023-2030, henceforth.

LATEST TRENDS 

Increasing Promotional Activities to Raise Awareness to Propel Market Growth

In recent years, the U.S. market had witnessed a significant trend in terms of the surge in awareness programs by key players. These initiatives have propelled product adoption in the market, leading to an increase in the number of botulinum toxin procedures. Such a scenario has led to these products gaining momentum in various aesthetic and therapeutic areas. Amidst the COVID-19 pandemic, several companies in the U.S. launched various campaigns to disseminate awareness amongst the people.

• For instance, in September 2020, Merz Aesthetics collaborated with R&B star Teyana Taylor for their Xeomin campaign. This campaign will promote its anti-wrinkle Xeomin treatment. This marketing initiative by the company will increase awareness regarding their product and, thus, drive market growth.

Moreover, promotional activities by key players using social media platforms are also becoming essential marketing tools. Thus, rising demand for these products in recent years is expected to boost the market expansion during the forecast period.

DRIVING FACTORS

Increasing Demand and Dramatic Shift Towards Non-Invasive to Boost the Market Growth

The demand for aesthetic procedures has been booming rapidly over the past few decades. The strong urge to look attractive has increased the demand for cosmetic procedures in the U.S. For instance, according to the International Society of Aesthetic and Plastic Surgery (ISAPS) in 2021, 5,355,604 non-surgical aesthetic procedures were performed in the U.S. Additionally, the adoption of these products amongst the aging population in the U.S. is also a critical driving factor for the market growth.

Furthermore, the rise in these non-invasive cosmetic procedures is due to the gradual shift in people looking for simple, pain-free methods to look youthful and healthy without invasive cosmetic surgeries. Thus, the growing demand for minimally invasive procedures has also led companies to focus extensively on launching advanced products in the market. Such factors are expected to boost market growth.

Growing R&D Initiatives for Additional Indication Approvals to Boost the Market Expansion

The key market players are strongly focusing on research and development activities for the U.S. market. The rise in the number of aesthetic procedures in multiple healthcare facilities has led to the vital need for market players to diversify their product portfolio in the U.S. This factor has led major players to be engaged in research activities for approvals for their innovative products. Also, undergoing research studies by key players is expected to lead to strong product adoption by proving product safety and efficacy.

• According to a study published on Clinicaltrials.gov in 2023, a study evaluated BOTOX injections' efficacy in terms of migraine prevention with episodic migraine amongst adults. The sponsor of this clinical study was the U.S. based company AbbVie Inc. Such factors leading to approvals for critical indications are driving the growth of the market in the U.S.

RESTRAINING FACTORS

Relative Side Effects and Presence of Counterfeit Products Limits the Market Growth

Despite robust demand and utilization of neurotoxin products, there are some factors that are limiting the market growth in the U.S. These factors include the rising cases of counterfeit products in the market. These counterfeit products may lead to serious life-threatening events. Though the U.S. FDA has stringent regulatory policies for aesthetic products, some recent cases of counterfeit products have occurred in the market. For instance, according to an article published by the U.S. Department of Homeland Security in 2020, the U.S. Customs and Border Protection (CBP) officers had seized multiple packages of counterfeit Botox injections at a Cincinnati express consignment facility. The shipment was valued at over USD 24,000.0. Such a scenario deters product adoption in the market.

Also, it is reported that these procedures may lead to certain serious side effects. Common side effects of these procedures include pain, swelling, headache, etc. Such a scenario deters product adoption and thus impedes market growth throughout the forecast period.

SEGMENTATION

By Application Analysis

Rising Awareness through Campaigns Enabled the Therapeutic Segment to Dominate Market in 2022

Based on application, the U.S. market is categorized into therapeutics and aesthetics. The therapeutics segment is further sub-categorized into chronic migraine, spasticity, overactive bladder, cervical dystonia, blepharospasm, and others.

The therapeutics segment captured a significant U.S. botulinum toxin market share in 2022. It is expected to exhibit a remarkable CAGR during the forecast period. The dominance of this segment is associated with the increasing usage of these products in the treatment of a variety of chronic diseases and several regulatory approvals in the U.S. Also, the rising number of campaigns by market players to disseminate product awareness contributes to market growth. According to an article published by Fierce Pharma in 2020, AbbVie launched a social media campaign that recruited health influencers and utilized the hashtag #ChronicMigraineMonday. This campaign planned to reach an estimated 3 million individuals suffering from chronic migraine.

The aesthetics segment holds the second-highest share in the U.S. market. This growth can be attributed due to the robust demand for botulinum toxin leading to an increasing number of non-invasive surgeries and a number of product launches for various aesthetic applications.

By Type Analysis

Robust Product Approvals by U.S. FDA Enabled Type A to Hold Major Market Share in 2022 

Based on type, the market is categorized into botulinum toxin type A and type B.

The type A segment captured the highest market share in 2022. Cosmetic procedures are commonly performed by this type. The increasing number of product approvals for certain new indications has primarily driven segmental growth.

• For instance, in October 2022, Hugel, Inc. resubmitted the BLA for its botulinum toxin called Botulax for the indication of glabellar lines to the U.S. FDA.

The type B held the second most dominant position in the market. Several ongoing clinical trial activities and strategic initiatives by key players are some of the factors that will contribute to the segment's growth in the forecast period.

By End-user Analysis

Increased Demand for Botox Products Enables the Specialty & Dermatology Clinics Dominance in 2022 

Based on end-user, the market is classified into specialty & dermatology clinics, hospitals & clinics, and others.

The specialty & dermatology clinics segment captured the maximum market share in 2022. A significant proportion of these procedures are conducted in specialty & dermatology clinics compared to hospitals. Also, several of these clinics offer additional services such as teleconsultations for these procedures which enhances the segment’s growth.

The hospitals & clinics held the second highest position in terms of market share. The growing adoption of the product and favorable reimbursement facility in the market also contributes to the segment's growth. Furthermore, the others segment accounted for the third-largest market share in 2022. A significant number of procedures for multiple applications are also conducted in ambulatory centers, which has led to the growth of the others segment.

• According to the American Society for Aesthetic Plastic Surgery data, in 2020, approximately 45.0% of cosmetic procedures were conducted in an ambulatory surgical facility.

KEY INDUSTRY PLAYERS

AbbVie Leads the U.S. Market in 2022 with Strong Focus on Product Launches

The market’s competitive landscape depicts a consolidated nature. The key company of AbbVie Inc. accounted for a significant proportion of the market share in 2022. AbbVie Inc. is one of the leading players in the market. The company's prominent position in the market is due to its strong focus on mergers & acquisitions, new product launches, and collaborations to expand its portfolio. For instance, in February 2022, Healis Therapeutics acquired the exclusive license for a botulinum toxin patent from AbbVie to develop the candidate to treat the major depressive disorder (MDD).

Similarly, companies such as Ipsen Pharma and Merz Pharma held a considerable market share. Positive results of clinical trials to introduce new products have strengthened the company’s market presence. Furthermore, other prominent companies like GALDERMA and HUGEL, Inc. are focusing on gaining a substantial share of the market in the forecast period. Increasing focus on product awareness through campaigns contributes to the company’s growth. For instance, in October 2022, Galderma continued its partnership with National Breast Cancer Foundation Inc. (NBCF). They featured the personal stories and treatment journeys of breast cancer survivors who received Restylane, Dysport (abobotulinumtoxinA) and/or Sculptra, in a campaign on Galderma’s social channels during Breast Cancer Awareness Month.

LIST OF KEY MARKET PLAYERS PROFILED:

• AbbVie Inc. (U.S.)


• Ipsen Pharma (France)


• Revance Therapeutics, Inc. (U.S.)


• Merz Pharma (Germany)


• Medytox (South Korea)


• GALDERMA (Switzerland)


• HUGEL, Inc. (Republic of Korea)


• Evolus, Inc. (U.S.)


• Supernus Pharmaceuticals, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• July 2020: Allergan, an AbboVie company, announced that USFDA had approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX to treat spasticity in pediatric patients two years of age and older, including those with lower limb spasticity caused by cerebral palsy.


• July 2020: FDA approved the expanded use of Dysport for treating upper and lower limb spasticity in pediatric patients (> two years).


• June 2020: Allergan plc (AbbVie Inc.) announced that the U.S. FDA accepted their supplemental Biologics License Application (sBLA)  of BOTOX  (onabotulinumtoxinA) for the treatment of neurogenic detrusor overactivity in pediatric patients.


• September 2019: Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced USFDA approval of the expanded application of Dysport (abobotulinumtoxinA) for treating upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy (CP).


• October 2019: Allergan plc (AbbVie Inc.) announced that the U.S. FDA approved their supplemental Biologics License Application (sBLA)  for BOTOX for the treatment of pediatric patients (2-17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy.

REPORT COVERAGE

The market report depicts a detailed industry analysis. It highlights product, application, pricing analysis, and regulatory and reimbursement scenarios. Furthermore, the market research report provides insights into COVID-19's impact and market trends and highlights the key industry developments in this market. Additionally, the report consists of several factors that contribute to this market's growth. The report also provides a competitive share analysis of the market.

Report Scope & Segmentation